A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma
ConditionMultiple Myeloma
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorMemorial Sloan Kettering Cancer Center
About this trial
The researchers are doing this study to find out whether combining teclistamab and mezigdomide is a safe and effective treatment approach in people with relapsed/refractory multiple myeloma (MM).
Eligibility criteria
Qualifiers
Patients with relapsed or refractory multiple myeloma who have been treated with a proteasome inhibitor, an IMiD, and an anti-CD38 antibody. Patients who have been treated with at least 2 prior lines of therapy are eligible. Multiple myeloma is defined by the International Myeloma Working Group (IMWG) updated criteria.
Serum myeloma (M)-protein greater than or equal to 0.5 g/dL (5 g/L).
Urine M-protein greater or equal to 200 mg/24 h.
Involved light chain (either kappa or lambda) >10 mg/dL with an abnormal kappa: lambda ratio
Disqualifiers
Prior treatment with a BCMA targeted bispecific antibody
Prior treatment with mezigdomide
Systemic anti-myeloma therapy (including systemic steroids) within ≤14 days, or plasmapheresis within 7 days prior to the first dose of study drug.
Use of an investigational drug within 21 days or five half-lives (whichever is longer) preceding the first dose of study drug.
Trial design
Treatments tested in this trial
- Teclistamab
- Mezigdomide
Treatment groups
18 Participants
are divided into 3 treatment groupsSponsors and collaborators
Memorial Sloan Kettering Cancer Center
Lead sponsor
Bristol-Myers Squibb
Collaborator
Johnson & Johnson
Collaborator
Source ClinicalTrials.gov